BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Stocks in this Quantisnow insightHealth Care
Historical context for BNTX
Across the 28 sessions after earlier BNTX headlines, the stock closed higher 14 times and lower 14 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BNTX | SPY |
|---|---|---|---|
| Oct 22, 2026 | BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | -1.8% | -1.2% |
| Oct 20, 2026 | BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 | +2.2% | +0.3% |
| Oct 19, 2026 | BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 | +1.7% | +0.4% |
| Oct 13, 2026 | BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer | -7.1% | -0.0% |
| Oct 8, 2026 | Argus initiated coverage on BioNTech | -3.3% | -0.4% |
| Sep 14, 2026 | BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients | +2.2% | -0.4% |
Quantisnow market dataNASDAQ
BNTX
BioNTech SE
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Get push alerts for BNTX
Full BNTX profile on Quantisnow Follow BNTX and get a push notification the moment its next story breaks.